 |
Christopher S. Henney, Ph.D, D.Sc.
Chairman and Director
Oncothyreon Inc. Committee Membership: Compensation Committee, Corporate Governance and Nominating Committee
CHRISTOPHER S. HENNEY Ph.D., D.Sc. has served as the chairman of our Board of Directors since September 2006 and as a member of our Board of Directors since March 2005. From 1995 to 2003, Dr. Henney was chairman and chief executive officer of Dendreon Corporation, a publicly traded biotechnology company that he co-founded. Dr. Henney was also a co-founder of Immunex Corporation and ICOS Corporation, both publicly traded biotechnology companies. Dr. Henney currently serves as a vice-chairman of the Board of Directors of Cyclacel Pharmaceuticals, a development-stage biopharmaceuticals company and as a member of the Board of Directors of AVI BioPharma, Inc. Dr. Henney received a Ph.D. in experimental pathology from the University of Birmingham, England, where he also obtained his D.Sc. for contributions in the field of immunology. Dr. Henney is a former professor of immunology and microbiology and has held faculty positions at Johns Hopkins University, the University of Washington and the Fred Hutchinson Cancer Research Center.
return to top ^
Richard L. Jackson, Ph.D.
Director
Oncothyreon Inc. Committee Membership: Compensation Committee, Corporate Governance and Nominating Committee
RICHARD L. JACKSON, Ph.D. has been a member of our Board of Directors since May 2003. Dr. Jackson is president of Jackson Associates, LLC, a biotechnology and pharmaceutical consulting company. Since September 2006, Dr. Jackson has also been president and chief executive officer of Ausio Pharmaceuticals, LLC, a drug development company. From May 2002 to May 2003, Dr. Jackson was president, chief executive officer and chairman of the Board of Directors of EmerGen, a biotechnology company. From November 1998 to January 2002, Dr. Jackson served as Senior Vice President, Research and Development for Atrix Laboratories, a biotechnology company. From January 1993 to July 1998, Dr. Jackson served as senior vice president, discovery research, at Wyeth-Ayerst Laboratories, the pharmaceuticals division of American Home Products Corporation.
return to top ^
Robert L. Kirkman, M.D.
Director, President and CEO
ROBERT L. KIRKMAN, M.D. has served as our president and chief executive officer and been a member of our Board of Directors since September 2006. From 2005 to 2006, Dr. Kirkman was acting president and chief executive officer of Xcyte Therapies, which concluded a merger with Cyclacel Pharmaceuticals, both development-stage biopharmaceuticals companies, in March of 2006. From 2004 to 2005, Dr. Kirkman was chief business officer and vice president of Xcyte. From 1998 to 2003, Dr. Kirkman was vice president, business development and corporate communications of Protein Design Labs, a biopharmaceuticals company. Dr. Kirkman holds an M.D. degree from Harvard Medical School and a B.A. in economics from Yale University.
return to top ^
Daniel K. Spiegelman, M.B.A.
Director
Oncothyreon Inc. Committee Membership: Audit Committee, Corporate Governance and Nominating Committee
DANIEL K. SPIEGELMAN, M.B.A. has been a member of our Board of Directors since June 2008. From 1998 to 2009, Mr. Spiegelman was employed at CV Therapeutics, Inc., a biopharmaceutical company, most recently as senior vice president and chief financial Officer. From 1992 to 1998, Mr. Spiegelman was an employee at Genentech, Inc., a biotechnology company, and most recently as treasurer. Mr. Spiegelman also serves as a member of the board of directors of Affymax, Inc., a publicly-traded biopharmaceuticals company and Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceuticals company. Mr. Spiegelman received his B.A. and M.B.A. from Stanford University.
return to top ^
W. Vickery Stoughton, B.Sc., M.B.A
Director
Oncothyreon Inc. Committee Membership: Audit Committee, Compensation Committee
W. VICKERY STOUGHTON, M.B.A. has been a member of our Board of Directors since June 1997. Since August 2006, Mr. Stoughton has served as president and chief executive officer of MagneVu Corporation, a medical devices company. From 1996 to 2002, Mr. Stoughton was chairman and chief executive officer of Careside Inc., a research and development, medical devices company. From October 1995 to July 1996, Mr. Stoughton was president of SmithKline Beecham Diagnostics Systems Co., a diagnostic services and product company, and prior to October 1995 he served as president of SmithKline Beecham Clinical Laboratories, a clinical laboratory company. Mr. Stoughton is a member of the Board of Directors of SunLife Financial, a financial services company. Mr. Stoughton received his B.S. in chemistry from St. Louis University and his M.B.A. from the University of Chicago.
return to top ^
Douglas E. Williams, Ph.D.
Director
Oncothyreon Inc. Committee Membership: Audit Committee
DOUGLAS E. WILLIAMS, PH.D. joined ZymoGenetics in 2004 and has served as a director and Chief Executive Officer since January 2009. He has held senior level positions at a number of prominent biotechnology companies, including Seattle Genetics, Inc., Immunex Corporation, and Amgen, Inc. As Executive Vice President and Chief Technology Officer at Immunex, Dr. Williams played a significant role in the discovery and early development of Enbrel, the first biologic approved for the treatment of rheumatoid arthritis. Dr. Williams currently serves as a director of Array BioPharma Inc. and Aerovance, Inc. Dr. Williams received a B.S. (magna cum laude) in Biological Sciences from the University of Massachusetts, Lowell and a Ph.D. in Physiology from the State University of New York at Buffalo, Roswell Park Cancer Institute Division.
return to top ^
|
|
